Enovix Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended January 2, 2022, compared with the year ended December 31, 2020. Enovix changed its fiscal year-end to a 52/53-week calendar during 2021; prior-period results were not restated. The company completed its business combination with Rodgers Silicon Valley Acquisition Corp. on July 14, 2021 and is an early-stage battery developer.
Business context and operating progress
Enovix develops silicon-anode lithium-ion batteries using its proprietary 3D cell architecture and roll-to-stack manufacturing process. It had not begun commercial production and reported no product revenue for either year. Fab-1 in Fremont was operational, and the company began shipping customer qualification cells in January 2022. Management forecast first commercial product revenue in Q2 2022.
The company cited design wins across wearables, mobile communications, computing and AR/VR, and reported a $1.5 billion revenue funnel in Q4 2021. This is the potential value of a full production year for engaged customer projects—not recognized revenue, contracted orders, or a guaranteed forecast.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Recognized revenue | No service or product revenue recognized | No service or product revenue recognized | — |
| Operating expenses | $69.5 million | $23.5 million | Up 195% |
| Operating loss | $(69.5) million | $(23.5) million | Loss increased |
| Net loss | $(125.9) million | $(39.7) million | Loss increased 217% |
| Net loss per share | $(1.07) | $(0.49) | — |
| Cash used in operating activities | $(51.3) million | $(20.1) million | Cash use increased |
| Capital expenditures | $43.6 million | $27.0 million | Increased |
| Free cash flow (non-GAAP) | $(94.9) million | $(47.0) million | Cash use increased |
Gross margin is not meaningfully assessable because no revenue was recognized. FY2021 research and development expense was $37.9 million, up 162%; selling, general and administrative expense was $29.7 million, up 420%. Management attributed increases mainly to hiring, stock-based compensation, facilities and tooling, public-company costs, and transaction-related professional fees.
At January 2, 2022, cash and cash equivalents were $385.3 million, working capital was $377.5 million, total assets were $482.6 million, and stockholders’ equity was $326.1 million. The company had no outstanding debt. Its balance sheet included a $124.3 million liability for private placement warrants. Net cash provided by financing activities was $451.1 million, including $405.2 million from the business combination and PIPE financing and $77.2 million from public warrant exercises, partly offset by transaction costs and debt repayment. Enovix reported $373.7 million in net business-combination proceeds. It also reported receiving $52.8 million of additional warrant-exercise proceeds in January 2022.
Material changes and unusual items
- Net loss widened substantially, reflecting higher operating spending and a $56.1 million loss from changes in fair value of warrant liabilities, compared with $13.8 million in FY2020. This fair-value expense was non-cash; it materially affected reported earnings.
- Operating cash use more than doubled and capital expenditures rose as Enovix built out manufacturing equipment and Fab-1.
- Stock-based compensation expense increased to $10.7 million from $0.7 million.
- FY2020 included a $1.6 million gain from forgiveness of a Paycheck Protection Program loan; no such gain was reported in FY2021.
- Deferred revenue was $7.9 million at year-end, against $4.6 million of deferred contract costs. These balances relate to engineering contracts whose final performance milestones had not yet been met.
Outlook, commentary and risks
Management expected cash resources, including business-combination and warrant proceeds, to fund requirements for at least the next 12 months, assuming no significant delays. It planned to scale output at Fab-1, order a new pilot line, pursue a second manufacturing facility (Fab-2), and target a next-generation production line for commercial production by mid-2023. The longer-term plan includes expansion toward capacity supporting $1.0 billion in annualized revenue, but this is a plan, not a reported result or guarantee.
Key execution risks include first-of-its-kind manufacturing scale-up, yield and throughput improvement, customer qualification and conversion of design wins into orders, supply availability and costs, and access to additional facilities and capital. The company also cited battery performance, safety, cycle life, competition, customer concentration, COVID-related supply disruptions, and the possibility that its energy-density roadmap may not be achieved. Enovix’s energy-density and cycle-life statements are company estimates and development claims; the filing notes that not all first-year product specifications had been achieved.
Contingencies included a pending attorneys’ fees and costs motion following dismissal of litigation concerning the business combination, and a January 2022 putative wage-and-hour class action filed by two former employees. The filing does not provide a clear estimate of potential loss for these matters. Enovix reported that earlier internal-control material weaknesses had been remediated, but management did not assess internal control over financial reporting for FY2021, and the auditor did not provide an internal-control attestation. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether Fab-1 achieves commercial production, customer qualification, targeted yields and throughput, and the stated Q2 2022 revenue timing.
- How much of the $1.5 billion revenue funnel becomes binding orders, at what timing and pricing; the funnel is not equivalent to backlog.
- Independent customer evidence for product performance, cycle life, safety, and energy density, as well as achievement of customer specifications.
- Cash burn, capital spending, liquidity needs, and funding required to build Fab-2 and other planned capacity; management’s 12-month cash assessment depends on assumptions.
- The effects of warrant accounting and future warrant exercises, including potential dilution and the large non-cash fair-value swings.
- Outcomes and any financial exposure from the pending litigation and wage-and-hour action, and the effectiveness of financial reporting controls as the company scales.